<p>在一个充满波动和地缘政治紧张局势的一周，全球市场面临新的挑战，主要的美国股票指数因贸易担忧而出现下跌。尽管出现这些波动，美国 GDP 增长的上调为投资者提供了一个积极的信号，突显出寻求具有强大基本面的成长公司的潜在机会。在这种环境下，拥有高内部持股的股票尤其吸引人，因为它们通常表明公司运营和战略愿景最接近的人对公司的信心。</p>
<h3>全球内部持股高的十大成长公司</h3>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>名称</strong></td>
<td><strong>内部持股</strong></td>
<td><strong>收益增长</strong></td>
</tr>
<tr>
<td>UTI (KOSDAQ:A179900)</td>
<td>24.7%</td>
<td>120.7%</td>
</tr>
<tr>
<td>Seers Technology (KOSDAQ:A458870)</td>
<td>32%</td>
<td>78.8%</td>
</tr>
<tr>
<td>Modetour Network (KOSDAQ:A080160)</td>
<td>12.7%</td>
<td>41.8%</td>
</tr>
<tr>
<td>Loadstar Capital K.K (TSE:3482)</td>
<td>31%</td>
<td>23.6%</td>
</tr>
<tr>
<td>Laopu Gold (SEHK:6181)</td>
<td>34.8%</td>
<td>34.4%</td>
</tr>
<tr>
<td>KebNi (OM:KEBNI B)</td>
<td>35%</td>
<td>73%</td>
</tr>
<tr>
<td>J&amp;V Energy Technology (TWSE:6869)</td>
<td>17.9%</td>
<td>27.1%</td>
</tr>
<tr>
<td>FUNDINNOInc (TSE:462A)</td>
<td>33.4%</td>
<td>41.5%</td>
</tr>
<tr>
<td>Fulin Precision (SZSE:300432)</td>
<td>10.6%</td>
<td>63.7%</td>
</tr>
<tr>
<td>CD Projekt (WSE:CDR)</td>
<td>29.7%</td>
<td>48.7%</td>
</tr>
</tbody>
</table>
<p>点击这里查看我们快速成长的全球高内部持股公司的 829 只股票的完整列表。</p>
<p>让我们深入探讨一些筛选出的优质选择。</p>
<h2>Aimed Bio (KOSDAQ:A0009K0)</h2>
<p><strong>Simply Wall St 成长评级：</strong> ★★★★★☆</p>
<p><strong>概述：</strong> Aimed Bio Inc. 专注于开发针对脑部疾病的治疗解决方案，包括神经肿瘤和退行性疾病，市值约为 3.70 万亿韩元。</p>
<p><strong>运营：</strong> 该公司通过研究、开发、生产和销售针对脑部疾病的抗体治疗产品，产生了 207.1 亿韩元的收入。</p>
<p><strong>内部持股：</strong> 34.4%</p>
<p><strong>收益增长预测：</strong> 每年 87.4%。</p>
<p>Aimed Bio 最近完成了 707.3 亿韩元的首次公开募股，显示出市场的强烈兴趣。预计该公司将实现显著增长，收入预计每年增长 31.9%，超过韩国市场的平均水平。预计收益将以每年 87.42% 的速度增长，预计在三年内实现盈利。尽管股价波动较大，且交易价格低于估计的公允价值 20.9%，但内部交易保持稳定，近期没有显著的买入或卖出活动。</p>
<ul>
<li>点击这里了解 Aimed Bio 的细微差别，查看我们的详细分析未来增长报告。</li>
<li>我们最近的估值报告指出，Aimed Bio 股票在市场上可能被高估。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/59f4bc68-dbed-48af-8bda-cbd666ae66fc/chart/ownership-breakdown?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/59f4bc68-dbed-48af-8bda-cbd666ae66fc/chart/ownership-breakdown"/></p>
<p>截至 2026 年 1 月 KOSDAQ:A0009K0 的持股结构</p>
<h2>Oscotec (KOSDAQ:A039200)</h2>
<p><strong>Simply Wall St 成长评级：</strong> ★★★★★★</p>
<p><strong>概述：</strong> Oscotec Inc. 是一家生物技术公司，涉及药物开发、功能材料和牙科骨移植材料业务，市值为 2 万亿韩元。</p>
<p><strong>运营：</strong> 公司的收入分为新药业务部门 199.1 亿韩元、医疗业务部门 18.4 亿韩元、功能材料 4.0781 亿韩元和食品业务 10.8 亿韩元。</p>
<p><strong>内部持股：</strong> 12.7%</p>
<p><strong>收益增长预测：</strong> 每年 116.4%。</p>
<p>Oscotec 的增长潜力体现在其预计每年收入增长 78.2%，超过韩国市场平均水平。预计该公司将在三年内实现盈利，收益预计每年显著增长 116.36%。尽管最近出现财务亏损和股价波动较大，Oscotec 的交易价格远低于其估计的公允价值，且内部持股保持稳定，近期没有显著的买入或卖出活动。</p>
<ul>
<li>点击这里深入了解 Oscotec 的具体情况，查看我们的详细增长预测报告。</li>
<li>在审查我们最新的估值报告后，Oscotec 的股价可能过于乐观。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/e1610900-f7d6-458a-aa37-9f8236dc7ec7/chart/ownership-breakdown?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/e1610900-f7d6-458a-aa37-9f8236dc7ec7/chart/ownership-breakdown"/></p>
<p>截至 2026 年 1 月 KOSDAQ:A039200 的持股结构</p>
<h2>BHI (KOSDAQ:A083650)</h2>
<p><strong>Simply Wall St 成长评级：</strong> ★★★★★☆</p>
<p><strong>概述：</strong> BHI 有限公司在全球范围内开发、制造和供应发电设备，市值为 2.25 万亿韩元。</p>
<p><strong>运营：</strong> 公司的收入主要来自其机械与工业设备部门，产生了 656.37 亿韩元的收入。</p>
<p><strong>内部持股：</strong> 34.4%</p>
<p><strong>收益增长预测：</strong> 每年 27.2%。</p>
<p>BHI 与 Red Post Energy 和 BASIC Equipment 的战略联盟旨在加速美国发电项目，利用 BHI 的制造和融资能力。这使 BHI 在数据中心和人工智能基础设施推动的能源需求上升中具备增长潜力。尽管股价波动较大，过去一年收益显著增长，预测显示收入将继续以每年 28.6% 的速度增长，超过市场平均水平。最近的收益报告显示出显著的利润增长，反映出强劲的运营表现。</p>
<ul>
<li>解锁我们对 BHI 股票分析的全面见解，查看此增长报告。</li>
<li>根据我们最近的估值报告，BHI 的交易价格似乎超出了其估计价值。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/1f2fd2f7-0df0-48ba-a38a-2917c982559c/chart/ownership-breakdown?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/1f2fd2f7-0df0-48ba-a38a-2917c982559c/chart/ownership-breakdown"/></p>
<p>截至 2026 年 1 月 KOSDAQ:A083650 的持股结构</p>
<h2>总结</h2>
<ul>
<li>点击这里深入了解 829 家快速成长的全球高内部持股公司的全貌。</li>
<li>寻找其他投资？探索 23 家领先量子计算公司的顶尖企业，它们正在引领下一代技术革命，并在量子算法、超导量子比特和前沿研究方面取得突破。</li>
</ul>
<p><em>这篇来自 Simply Wall St 的文章具有一般性。<strong>我们仅基于历史数据和分析师预测提供评论，采用无偏见的方法，我们的文章并不旨在提供财务建议。</strong> 它不构成买卖任何股票的推荐，也未考虑您的目标或财务状况。我们的目标是为您提供以基本数据驱动的长期分析。请注意，我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中均没有持仓。该分析仅考虑内部人士直接持有的股票，不包括通过其他工具（如公司和/或信托实体）间接持有的股票。所有预测的收入和盈利增长率均以年化（每年）增长率的形式表示，时间范围为 1-3 年。</em></p>

<p>在全球市场波动的一周，美国股指因贸易担忧而下跌，但美国 GDP 增长的上调为投资者提供了机会。内部持股比例高的公司，如 Aimed Bio、Oscotec 和 BHI，显示出高达 116% 的盈利增长预期。Aimed Bio 专注于脑部疾病治疗，Oscotec 专注于药物开发，而 BHI 则专注于发电设备，尽管市场波动，这些公司都显示出强劲的基本面。内部持股比例表明对其战略愿景的信心，使它们成为有吸引力的投资选择</p>

<p>In a week marked by volatility and geopolitical tensions, global markets have faced renewed challenges, with major U.S. stock indexes experiencing declines amid trade concerns. Despite these fluctuations, the upward revision of U.S. GDP growth offers a silver lining, underscoring potential opportunities for investors seeking growth companies with strong fundamentals. In this environment, stocks with high insider ownership can be particularly appealing as they often indicate confidence from those closest to the company’s operations and strategic vision.</p>
<div class="lb-trans"><p>在一个充满波动和地缘政治紧张局势的一周，全球市场面临新的挑战，主要的美国股票指数因贸易担忧而出现下跌。尽管出现这些波动，美国 GDP 增长的上调为投资者提供了一个积极的信号，突显出寻求具有强大基本面的成长公司的潜在机会。在这种环境下，拥有高内部持股的股票尤其吸引人，因为它们通常表明公司运营和战略愿景最接近的人对公司的信心。</p>
</div><h3>Top 10 Growth Companies With High Insider Ownership Globally</h3>
<div class="lb-trans"><h3>全球内部持股高的十大成长公司</h3>
</div><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Name</strong></td>
<td><strong>Insider Ownership</strong></td>
<td><strong>Earnings Growth</strong></td>
</tr>
<tr>
<td>UTI (KOSDAQ:A179900)</td>
<td>24.7%</td>
<td>120.7%</td>
</tr>
<tr>
<td>Seers Technology (KOSDAQ:A458870)</td>
<td>32%</td>
<td>78.8%</td>
</tr>
<tr>
<td>Modetour Network (KOSDAQ:A080160)</td>
<td>12.7%</td>
<td>41.8%</td>
</tr>
<tr>
<td>Loadstar Capital K.K (TSE:3482)</td>
<td>31%</td>
<td>23.6%</td>
</tr>
<tr>
<td>Laopu Gold (SEHK:6181)</td>
<td>34.8%</td>
<td>34.4%</td>
</tr>
<tr>
<td>KebNi (OM:KEBNI B)</td>
<td>35%</td>
<td>73%</td>
</tr>
<tr>
<td>J&amp;V Energy Technology (TWSE:6869)</td>
<td>17.9%</td>
<td>27.1%</td>
</tr>
<tr>
<td>FUNDINNOInc (TSE:462A)</td>
<td>33.4%</td>
<td>41.5%</td>
</tr>
<tr>
<td>Fulin Precision (SZSE:300432)</td>
<td>10.6%</td>
<td>63.7%</td>
</tr>
<tr>
<td>CD Projekt (WSE:CDR)</td>
<td>29.7%</td>
<td>48.7%</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>名称</strong></td>
<td><strong>内部持股</strong></td>
<td><strong>收益增长</strong></td>
</tr>
<tr>
<td>UTI (KOSDAQ:A179900)</td>
<td>24.7%</td>
<td>120.7%</td>
</tr>
<tr>
<td>Seers Technology (KOSDAQ:A458870)</td>
<td>32%</td>
<td>78.8%</td>
</tr>
<tr>
<td>Modetour Network (KOSDAQ:A080160)</td>
<td>12.7%</td>
<td>41.8%</td>
</tr>
<tr>
<td>Loadstar Capital K.K (TSE:3482)</td>
<td>31%</td>
<td>23.6%</td>
</tr>
<tr>
<td>Laopu Gold (SEHK:6181)</td>
<td>34.8%</td>
<td>34.4%</td>
</tr>
<tr>
<td>KebNi (OM:KEBNI B)</td>
<td>35%</td>
<td>73%</td>
</tr>
<tr>
<td>J&amp;V Energy Technology (TWSE:6869)</td>
<td>17.9%</td>
<td>27.1%</td>
</tr>
<tr>
<td>FUNDINNOInc (TSE:462A)</td>
<td>33.4%</td>
<td>41.5%</td>
</tr>
<tr>
<td>Fulin Precision (SZSE:300432)</td>
<td>10.6%</td>
<td>63.7%</td>
</tr>
<tr>
<td>CD Projekt (WSE:CDR)</td>
<td>29.7%</td>
<td>48.7%</td>
</tr>
</tbody>
</table>
</div><p>Click here to see the full list of 829 stocks from our Fast Growing Global Companies With High Insider Ownership screener.</p>
<div class="lb-trans"><p>点击这里查看我们快速成长的全球高内部持股公司的 829 只股票的完整列表。</p>
</div><p>Let's dive into some prime choices out of the screener.</p>
<div class="lb-trans"><p>让我们深入探讨一些筛选出的优质选择。</p>
</div><h2>Aimed Bio (KOSDAQ:A0009K0)</h2>
<div class="lb-trans"><h2>Aimed Bio (KOSDAQ:A0009K0)</h2>
</div><p><strong>Simply Wall St Growth Rating:</strong> ★★★★★☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 成长评级：</strong> ★★★★★☆</p>
</div><p><strong>Overview:</strong> Aimed Bio Inc. focuses on developing therapeutic solutions for brain diseases, including neuro-oncological and degenerative conditions, with a market cap of approximately ₩3.70 trillion.</p>
<div class="lb-trans"><p><strong>概述：</strong> Aimed Bio Inc. 专注于开发针对脑部疾病的治疗解决方案，包括神经肿瘤和退行性疾病，市值约为 3.70 万亿韩元。</p>
</div><p><strong>Operations:</strong> The company generates revenue of ₩20.71 billion by researching, developing, producing, and selling antibody-based therapeutics for brain diseases.</p>
<div class="lb-trans"><p><strong>运营：</strong> 该公司通过研究、开发、生产和销售针对脑部疾病的抗体治疗产品，产生了 207.1 亿韩元的收入。</p>
</div><p><strong>Insider Ownership:</strong> 34.4%</p>
<div class="lb-trans"><p><strong>内部持股：</strong> 34.4%</p>
</div><p><strong>Earnings Growth Forecast:</strong> 87.4% p.a.</p>
<div class="lb-trans"><p><strong>收益增长预测：</strong> 每年 87.4%。</p>
</div><p>Aimed Bio recently completed a KRW 70.73 billion IPO, signaling strong market interest. The company is poised for significant growth, with revenue expected to increase by 31.9% annually, outpacing the Korean market's average. Earnings are forecasted to grow at an impressive 87.42% per year, with profitability anticipated in three years. Despite high share price volatility and trading below estimated fair value by 20.9%, insider transactions remain stable without substantial buying or selling activity recently.</p>
<div class="lb-trans"><p>Aimed Bio 最近完成了 707.3 亿韩元的首次公开募股，显示出市场的强烈兴趣。预计该公司将实现显著增长，收入预计每年增长 31.9%，超过韩国市场的平均水平。预计收益将以每年 87.42% 的速度增长，预计在三年内实现盈利。尽管股价波动较大，且交易价格低于估计的公允价值 20.9%，但内部交易保持稳定，近期没有显著的买入或卖出活动。</p>
</div><ul>
<li>Click here to discover the nuances of Aimed Bio with our detailed analytical future growth report.</li>
<li>Insights from our recent valuation report point to the potential overvaluation of Aimed Bio shares in the market.</li>
</ul>
<div class="lb-trans"><ul>
<li>点击这里了解 Aimed Bio 的细微差别，查看我们的详细分析未来增长报告。</li>
<li>我们最近的估值报告指出，Aimed Bio 股票在市场上可能被高估。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/59f4bc68-dbed-48af-8bda-cbd666ae66fc/chart/ownership-breakdown" alt="" original-src="https://images.simplywall.st/company/59f4bc68-dbed-48af-8bda-cbd666ae66fc/chart/ownership-breakdown"/></p>
<p>KOSDAQ:A0009K0 Ownership Breakdown as at Jan 2026</p>
<div class="lb-trans"><p>截至 2026 年 1 月 KOSDAQ:A0009K0 的持股结构</p>
</div><h2>Oscotec (KOSDAQ:A039200)</h2>
<div class="lb-trans"><h2>Oscotec (KOSDAQ:A039200)</h2>
</div><p><strong>Simply Wall St Growth Rating:</strong> ★★★★★★</p>
<div class="lb-trans"><p><strong>Simply Wall St 成长评级：</strong> ★★★★★★</p>
</div><p><strong>Overview:</strong> Oscotec Inc. is a biotechnology company involved in drug development, functional materials, and dental bone graft material businesses, with a market cap of ₩2 trillion.</p>
<div class="lb-trans"><p><strong>概述：</strong> Oscotec Inc. 是一家生物技术公司，涉及药物开发、功能材料和牙科骨移植材料业务，市值为 2 万亿韩元。</p>
</div><p><strong>Operations:</strong> The company's revenue segments are comprised of the New Drug Business Division at ₩19.91 billion, the Medical Business Sector at ₩1.84 billion, Functional Materials at ₩407.81 million, and the Food Business at ₩1.08 billion.</p>
<div class="lb-trans"><p><strong>运营：</strong> 公司的收入分为新药业务部门 199.1 亿韩元、医疗业务部门 18.4 亿韩元、功能材料 4.0781 亿韩元和食品业务 10.8 亿韩元。</p>
</div><p><strong>Insider Ownership:</strong> 12.7%</p>
<div class="lb-trans"><p><strong>内部持股：</strong> 12.7%</p>
</div><p><strong>Earnings Growth Forecast:</strong> 116.4% p.a.</p>
<div class="lb-trans"><p><strong>收益增长预测：</strong> 每年 116.4%。</p>
</div><p>Oscotec's growth potential is underscored by its forecasted revenue increase of 78.2% annually, outpacing the Korean market average. The company is expected to become profitable in three years, with earnings projected to grow significantly at 116.36% per year. Despite recent financial losses and high share price volatility, Oscotec trades well below its estimated fair value and maintains stable insider ownership without significant recent buying or selling activity.</p>
<div class="lb-trans"><p>Oscotec 的增长潜力体现在其预计每年收入增长 78.2%，超过韩国市场平均水平。预计该公司将在三年内实现盈利，收益预计每年显著增长 116.36%。尽管最近出现财务亏损和股价波动较大，Oscotec 的交易价格远低于其估计的公允价值，且内部持股保持稳定，近期没有显著的买入或卖出活动。</p>
</div><ul>
<li>Dive into the specifics of Oscotec here with our thorough growth forecast report.</li>
<li>Upon reviewing our latest valuation report, Oscotec's share price might be too optimistic.</li>
</ul>
<div class="lb-trans"><ul>
<li>点击这里深入了解 Oscotec 的具体情况，查看我们的详细增长预测报告。</li>
<li>在审查我们最新的估值报告后，Oscotec 的股价可能过于乐观。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/e1610900-f7d6-458a-aa37-9f8236dc7ec7/chart/ownership-breakdown" alt="" original-src="https://images.simplywall.st/company/e1610900-f7d6-458a-aa37-9f8236dc7ec7/chart/ownership-breakdown"/></p>
<p>KOSDAQ:A039200 Ownership Breakdown as at Jan 2026</p>
<div class="lb-trans"><p>截至 2026 年 1 月 KOSDAQ:A039200 的持股结构</p>
</div><h2>BHI (KOSDAQ:A083650)</h2>
<div class="lb-trans"><h2>BHI (KOSDAQ:A083650)</h2>
</div><p><strong>Simply Wall St Growth Rating:</strong> ★★★★★☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 成长评级：</strong> ★★★★★☆</p>
</div><p><strong>Overview:</strong> BHI Co., Ltd. develops, manufactures, and supplies power plant equipment globally, with a market cap of ₩2.25 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> BHI 有限公司在全球范围内开发、制造和供应发电设备，市值为 2.25 万亿韩元。</p>
</div><p><strong>Operations:</strong> The company's revenue primarily comes from its Machinery &amp; Industrial Equipment segment, generating ₩656.37 million.</p>
<div class="lb-trans"><p><strong>运营：</strong> 公司的收入主要来自其机械与工业设备部门，产生了 656.37 亿韩元的收入。</p>
</div><p><strong>Insider Ownership:</strong> 34.4%</p>
<div class="lb-trans"><p><strong>内部持股：</strong> 34.4%</p>
</div><p><strong>Earnings Growth Forecast:</strong> 27.2% p.a.</p>
<div class="lb-trans"><p><strong>收益增长预测：</strong> 每年 27.2%。</p>
</div><p>BHI's strategic alliance with Red Post Energy and BASIC Equipment aims to accelerate U.S. power generation projects, leveraging BHI’s manufacturing and financing capabilities. This positions BHI for growth amid rising energy demand driven by data centers and AI infrastructure. Despite a volatile share price, earnings grew significantly over the past year, with forecasts indicating continued revenue growth of 28.6% annually, surpassing market averages. Recent earnings reports show substantial profit increases, reflecting strong operational performance.</p>
<div class="lb-trans"><p>BHI 与 Red Post Energy 和 BASIC Equipment 的战略联盟旨在加速美国发电项目，利用 BHI 的制造和融资能力。这使 BHI 在数据中心和人工智能基础设施推动的能源需求上升中具备增长潜力。尽管股价波动较大，过去一年收益显著增长，预测显示收入将继续以每年 28.6% 的速度增长，超过市场平均水平。最近的收益报告显示出显著的利润增长，反映出强劲的运营表现。</p>
</div><ul>
<li>Unlock comprehensive insights into our analysis of BHI stock in this growth report.</li>
<li>In light of our recent valuation report, it seems possible that BHI is trading beyond its estimated value.</li>
</ul>
<div class="lb-trans"><ul>
<li>解锁我们对 BHI 股票分析的全面见解，查看此增长报告。</li>
<li>根据我们最近的估值报告，BHI 的交易价格似乎超出了其估计价值。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/1f2fd2f7-0df0-48ba-a38a-2917c982559c/chart/ownership-breakdown" alt="" original-src="https://images.simplywall.st/company/1f2fd2f7-0df0-48ba-a38a-2917c982559c/chart/ownership-breakdown"/></p>
<p>KOSDAQ:A083650 Ownership Breakdown as at Jan 2026</p>
<div class="lb-trans"><p>截至 2026 年 1 月 KOSDAQ:A083650 的持股结构</p>
</div><h2>Summing It All Up</h2>
<div class="lb-trans"><h2>总结</h2>
</div><ul>
<li>Gain an insight into the universe of 829 Fast Growing Global Companies With High Insider Ownership by clicking here.</li>
<li>Seeking Other Investments? Explore 23 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.</li>
</ul>
<div class="lb-trans"><ul>
<li>点击这里深入了解 829 家快速成长的全球高内部持股公司的全貌。</li>
<li>寻找其他投资？探索 23 家领先量子计算公司的顶尖企业，它们正在引领下一代技术革命，并在量子算法、超导量子比特和前沿研究方面取得突破。</li>
</ul>
</div><p><em>This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.</em></p>
<div class="lb-trans"><p><em>这篇来自 Simply Wall St 的文章具有一般性。<strong>我们仅基于历史数据和分析师预测提供评论，采用无偏见的方法，我们的文章并不旨在提供财务建议。</strong> 它不构成买卖任何股票的推荐，也未考虑您的目标或财务状况。我们的目标是为您提供以基本数据驱动的长期分析。请注意，我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中均没有持仓。该分析仅考虑内部人士直接持有的股票，不包括通过其他工具（如公司和/或信托实体）间接持有的股票。所有预测的收入和盈利增长率均以年化（每年）增长率的形式表示，时间范围为 1-3 年。</em></p>
</div>

3 Global Growth Companies With High Insider Ownership Expecting Up To 116% Earnings Growth

Simplywall

生物科技 ETF - VanEck Vectors

纳斯达克生物科技指数 ETF - iShares Nasdaq

OncoSec Medical Incorporated

Mustang Bio

动态生物技术与基因组 ETF - Invesco

纽交所高增长板生物技术指数 ETF - First Trust

标普生物技术 3 倍做空 - Direxion

AIM ImmunoTech Inc.

医药突破 ETF - ALPS

标普生物技术 ETF - SPDR

AIM IMMUNOTECH INC

Invesco Nasdaq Biotechnology ETF

2 倍做多纳斯达克生物技术 ETF - ProShares

三家全球增长型公司拥有高内部持股，预计盈利增长可达 116%